Sou Hu Cai Jing·2025-11-22 09:40Group 1 - The pharmaceutical and biotechnology industry is facing pressure from multiple factors such as centralized procurement price reductions and medical insurance cost control, leading to overall performance challenges [1] - Despite the industry's downturn, WuXi AppTec and Mindray Medical have demonstrated strong profitability, allowing them to stand out in the market and rank among the top 100 companies by net profit attributable to shareholders in Q3 2025 [1] - WuXi AppTec ranked 55th with a net profit attributable to shareholders of 12.076 billion yuan, reflecting a year-on-year growth of 84.84%, although it dropped three places compared to the half-year report [3] Group 2 - The innovative drug and contract research organization (CXO) industry chain is one of the few high-growth sub-sectors amidst the overall industry slump, with WuXi AppTec benefiting directly from this trend [5] - Mindray Medical, operating in the medical device sector, is currently affected by tendering rhythms but has shown strong resilience through internationalization and technological upgrades [5]